Nature’s Toolbox, a Rio Rancho-based life sciences company, announced Thursday that it has raised $47.5 million in Series B financing.

Led by RA Capital Management, the investment will fuel the advancement of the Nature’s Toolbox (NTx) biomanufacturing platforms, NTxscribe and NTxpress.

Acceleration of these technology foundations will enable distribution of manufacturing capabilities globally, ultimately providing solutions to prepare for future pandemic events, personalized medicine therapy and increased access to vaccines and medicines.

“This financing will help us work toward our mission of delivering innovative biomanufacturing solutions designed to manufacture therapeutics in a more rapid, accessible and sustainable way. This was also the largest Series B round raised by a New Mexico life sciences company in recent history,” said Jamie Coffin, Ph.D., CEO of NTx. “We are thrilled to have RA Capital Management lead the round. This major commitment and the addition of Peter Kolchinsky, Ph.D., to our Board of Directors will accelerate NTx’s technology development and commercial penetration with leading biopharma, health care and government entities.”

The funding round for NTx is the largest for a New Mexico company so far this year.

According to NTX, “Historic challenges with conventional manufacturing processes and supply chain stability have slowed progress and increased costs for the development of critical vaccines and biologics. The NTxscribe platform is a cell-free, true continuous flow manufacturing system that addresses these challenges by delivering scalable RNA materials in a small footprint. NTxscribe is currently being deployed in BioPharma research and development to help expedite mRNA therapeutic development. It is also the technology being evaluated in the first Vaccines-on-Demand contract awarded by BARDA DRIVe for pandemic preparedness. NTxpress is a fully recombinant cell-free expression system that produces proteins while minimizing unwanted cellular metabolism.”

This approach is expected to revolutionize compound production with broad application in numerous markets including therapeutics, materials, chemicals and environmental. The Series B funding will accelerate NTx’s development of the NTxscribe and NTxpress platforms into commercially available solutions including the manufacturing of biomaterials for producing mRNA and proteins.

“Having low cost of goods is critical to unlocking the full societal value of any novel modality, and NTx has cracked the code for dramatically reducing the cost and scalability of producing mRNA,” said Peter Kolchinsky, Ph.D., managing partner at RA Capital Management, said. “NTx will help the entire field of mRNA, spanning scores of companies and hundreds of programs, to reach their global potential.”